Watchlist

Watchlist
Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam completes U.S. marketing application for patisiran for hATTR amyloidosis
Alnylam Pharmaceuticals (NASDAQ: ALNY ) has completed its rolling NDA submission to the FDA seeking approval for patisiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Hea…
Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Patisiran Could Become the First in a New Class of Medicines Known as RNAi Therapeutics Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to …
Your Daily Pharma Scoop: Gilead Remains Long-Term Story, Argenx Rallies, Bluebird Data
Content Analysis of coverage Stocks in the news Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar TPT subscribers only Trade Idea of the Day Subscriber Questions & Answers Catalyst Ru…
Alnylam expands U.S. ODD for Patisiran to treatment of transthyretin-mediated amyloidosis
Alnylam Pharmaceuticals(NASDAQ: ALNY ) announces that the FDA has granted a request to amend the orphan drug designation for patisiran to the treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis) . More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news,…
Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the U.S. Food and Drug Administration (FDA) has granted a request to amend the orphan drug designation for patisiran to the treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis)…
Akari's Coversin successful in mid-stage PNH study
A Phase 2 clinical trial, COBALT , assessing Akari Therapeutics' (NASDAQ: AKTX ) lead candidate Coversin in patients with paroxysmal nocturnal hemoglobinuria (PNH) met the primary endpoint of a statistically significant reduction in LDH (lactate dehydrogenase) to within 1.8x the upper lim…
Alnylam to Webcast Presentation at BMO Capital Markets Prescriptions for Success Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 9:00 am ET at the Westin Gr…
Medical Stocks: Investing For 2018
2017 has turned out to be a good year for medical stocks, with strong gains in biopharmaceuticals, medical devices, diagnostics and HMOs. This can be attributed to a strong overall stock market, a quieting of concerns regarding drug pricing, an unchanged ACA and an underlying 6% growth rate …
Biotech: Biding Its Time
Biotech Pulse The months of October and November have been unfavorable for biotechs as the sector has witnessed a sharp pullback. The Nasdaq Biotechnology Index ( IBB ), shown below, retreated 12% from its 52-week high posted in early October. Nasdaq Biotechnology Index ETF ((IBB)) Dur…
Your Daily Pharma Scoop: Roche Rallies, Alnylam Granted BTD, Celsion Soars
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Roche Today we will discuss an articl…
Alnylam Pharmaceuticals, Inc. (ALNY)